润尔乐滴眼液治疗翼状胬肉术后角膜上皮愈合不良的疗效观察

目的观察润尔乐滴眼液对翼状胬肉术后角膜上皮愈合不良的治疗效果。方法随机将48例翼状胬肉术后角膜上皮愈合不良患者分为2组,一组给予人工泪液滴眼,另一组给予润尔乐滴眼液滴眼,分别观察2组患者角膜上皮的修复情况。结果使用润尔乐滴眼液组临床症状缓解迅速,角膜上皮修复良好。结论对翼状胬肉术后角膜上皮愈合不良的患者使用润尔乐滴眼液滴眼,可以较好地缓解眼部刺激症状,并能有效地促进角膜上皮修复。     

PureVision纯视角膜接触镜的治疗应用观察（下）

接受观察病例共29例（31眼）,配戴治疗观察时间3～57天,平均20．9天。眼病诊断包括大泡性角膜病变6例（6眼）;单庖角膜炎合并角膜后弹力层膨出或小穿孔者5例（5眼）;化学烧伤角膜上皮缺损者6例（7眼）,其中1眼为酒精烧伤早期;角膜移植术或角膜穿破性外伤缝线刺激者3例（3眼）;丝状角膜炎3例（3眼）;角膜上皮糜烂2例（3眼）;反复性角膜上皮剥脱症1例（1眼）;     

角膜宁滴眼液治疗超声乳化白内障摘出术后角膜上皮损伤

目的观察角膜宁滴眼液对超声乳化白内障摘出术后角膜上皮损伤的治疗效果。方法随机将42例超声乳化白内障术后出现角膜上皮损伤患者分为两组,一组常规术后用药,一组加用角膜宁滴眼液,观察两组患者症状的改善和角膜上皮修复情况。结果加用角膜宁滴眼液组症状轻,角膜上皮修复快。结论给超声乳化术后角膜损伤患者加用角膜宁滴眼液,可改善症状,促进角膜上皮愈合。     

润洁萘扑维滴眼液治疗视疲劳的初步临床观察

目的评价润洁萘扑维滴眼液治疗视疲劳的临床效果。方法应用润洁萘扑维滴眼液治疗视疲劳42例,分别于用药前、用药后1、3、7、14d评估患者的症状和体征,同时观察药物的不良反应。结果与用药前相比,总积分(P<0.000)、异物感(P=0.003)、烧灼感(P=0.004)、眼痛(P=0.006)、流泪(P=0.014)、充血(P=0.01)积分于用药后1d下降,差异有统计学意义。畏光(P=0.001)、睑痉挛(P=0.026)、头晕头痛(P=0.005)积分于用药后3d下降,差异有统计学意义。除头晕头痛积分有反弹外(用药后7d及14dP>0.05),其余指标的积分均随着时间延长而逐渐下降。恶心呕吐症状在用药观察期间无明显改变。8例发生一过性眼局部不良反应,其中1例伴有轻微的头痛。结论润洁萘扑维滴眼液14d内能安全有效地缓解视疲劳的症状和体征。     

非斜视性视疲劳患者隐斜及调节功能的分析

目的:分析在临床工作中非斜视性视疲劳患者的双眼视功能,了解视疲劳患者中隐斜及调节功能的情况,为进行视觉训练康复提供理论依据。方法:回顾性分析天津市眼科医院验光配镜中心2008年7月~11月非斜视性视疲劳患者34例,进行双眼屈光检查、双眼视功能检查,并对其进行分析。结果:根据Morgan标准值进行分析,34例非斜视性视疲劳患者中,远水平隐斜异常23例(67.65%),其中外隐斜患者10例(29.41%),内隐斜患者13例(38.24%);近水平隐斜异常20例(58.82%),其中外隐斜患者12例(35.29%),内隐斜患者8例(23.53%)。92.65%患者单眼调节灵敏度异常,85.30%患者双眼调节灵敏度异常;48.53%患者单眼调节幅度低于其年龄段平均值;负相对调节异常比例(38.24%)明显高于正相对调节异常比例(2.90%),14.71%患者调节反应(BCC)异常。结论:视疲劳患者单眼调节灵敏度及双眼调节灵敏度明显降低,临床工作中不能忽略单/双眼调节灵敏度检查,在明确诊断视疲劳前应综合分析双眼视功能各个参数而不是分析某单一参数。     

讨论视觉训练治疗集合不足的效果

目的:通过对集合不足双眼视异常的患者进行视觉训练,观察双眼视的恢复及视疲劳的缓解情况,探讨视觉训练治疗患者集合不足及缓解视疲劳的疗效。方法:收集视光门诊集合不足双眼视异常患者36例,完成训练的31例,男性16例,女性20例,年龄最小5岁,最大35岁,平均年龄15岁。首先请患者填写症状问卷调查表,然后进行全面眼科检查,最后进行屈光检查和双眼视功能检查。根据检查结果,分别针对个人情况制定训练计划并进行训练,随访观察3到6个月,复查屈光度和双眼视功能。结果:集合不足的改善率为77.42%,视疲劳的缓解率为83.33%。结论:视觉训练治疗患者集合不足及缓解视疲劳症状效果较好。     

视疲劳诊断与处理流程

正视疲劳(asthenopia)是由于不良的视觉工作环境、视觉器官功能障碍、全身器质性疾病及心理异常诸因素单一或相互作用所致的视觉作业不能正常进行的一组症候群。视疲劳患者的病因和症状多种多样,临床诊断较为困难。由于视疲劳广泛地发生,因此科学地诊疗视疲劳在实际工作中非常重要,临床上我们设计出一套规范的视疲劳诊断与处理流程,通过这样的流程能更快速地找到顾客的视疲劳病因,并针对病因采取有效的治疗和处     

玻璃酸钠滴眼液在眼部A超检查中的应用观察

目的:本文分析玻璃酸钠滴眼液在眼部A超检查中的应用效果。方法:本文选择在2017年1月1日-2017年2月1日到我院眼科接受眼部A超检查的白内障患者100例,将患者分为实验组和参照组两组,每组各有50例患者,实验组患者在接受眼部A超检查时应用了玻璃酸钠滴眼液,参照组患者在接受眼部A超检查时未应用玻璃酸钠滴眼液,随后对比两组患者的角膜上皮损伤发生率。结果:相比较参照组患者而言,实验组患者的角膜上皮损伤发生率要低。结论:玻璃酸钠滴眼液在眼部A超检查中的应用,能够有效的改善患者角膜上皮损伤程度,适合被普遍应用到眼部A超检查中。     

经视觉训练后成人与青少年视疲劳症状缓解比较

目的:通过对双眼视异常有视疲劳症状的患者进行视觉训练,观察不同年龄患者双眼视的恢复及视疲劳的缓解情况,探讨视觉训练针对不同年龄患者缓解视疲劳的疗效。方法:收集视光门诊双眼视异常视疲劳患者97例,完成训练的73例,年龄最小9岁,最大43岁。首先请患者填写症状问卷调查表,这些有疲劳症状的患者的问卷分数都大于等于16分。然后进行全面眼科检查,最后进行屈光检查和双眼视功能检查,根据检查结果,分别针对个人情况制定训练计划并进行训练,随访观察1到6个月,复查屈光度和双眼视功能。结果:不同年龄段患者视疲劳的缓解率明显不同。结论:视觉训练缓解视疲劳症状疗效较好,但对不同年龄患者效果有明显差异。     

彩色多普勒超声与临床病理诊断甲状腺癌的效果观察

目的:分析彩色多普勒超声与临床病理诊断甲状腺癌的应用效果。方法:选取我院2018年1月～12月术后经病理证实的甲状腺癌患者40例,将术后病理检查结果与术前彩色多普勒超声检查结果进行对照。结果:40例甲状腺癌患者术前彩色多普勒超声检查的诊断符合率为72.5%;术前彩色多普勒超声检查诊断为乳头状癌的符合率为79.41%,滤泡状癌的符合率为25.0%,髓样癌的符合率为50.0%。彩色多普勒超声检查诊断乳头状癌的符合率与滤泡状癌、髓样癌符合率对比差异显著,p 0.05;滤泡状癌与髓样癌诊断符合率对比无显著差异,p 0.05。结论:彩色多普勒超声诊断甲状腺癌具有一定的临床优势,合理应用能够提高临床诊断准确率。但为了更全面观察甲状腺癌的病变组织情况,需要将临床病理检查作为重要的辅助手段,确保为患者制定更为科学、可靠的治疗方案。     

盐酸环喷托酯滴眼液散瞳和麻痹睫状肌效果和安全性的临床研究

目的评价盐酸环喷托酯滴眼液的疗效及安全性。方法采用多中心随机双盲阳性药平行对照试验。结果试验药麻痹睫状肌的效应强于对照药托吡卡胺滴眼液,持续时间长。而试验药散瞳效应慢于对照药,但持续时间较长,给药后75min试验药与对照药的散瞳效应相当。试验组和对照组的不良反应主要表现为结膜轻度充血和分泌物轻度增多。试验组和对照组发生率均为1．7％（刺激积分2分及以上均为2例）,两组比较差异无统计学意义。试验组和对照组均无明显升高正常人群眼压的作用。结论盐酸环喷托酯滴眼液在眼科检查中的散瞳和麻痹睫状肌的效果肯定,耐受性好,安全性高,值得临床推广应用,特别是其麻痹睫状肌的作用较强,持续时间不超过48h,特别适合需麻痹睫状肌功能的眼科检查。     

牛鼻软骨粉中硫酸软骨素的碱法提取及光谱分析

以牛鼻软骨为原料酶法制备软骨粉,采用稀碱液浸提和乙醇沉淀的方法提取硫酸软骨素(Chondroitin Sulfate,ChS),通过单因素和正交试验对碱解工艺进行优化,确定的最佳条件是:料水比1:6,NaOH浓度5%,温度40℃,浸提时间6h,在此条件下,提取率达到12.58%,葡萄糖醛酸含量为32.44%,硫酸软骨素纯度达82%。紫外光谱分析:样品在196nm处有多糖的吸收峰,未见蛋白质(280nm)与核酸(260nm)的特征吸收峰;红外光谱分析发现为典型的硫酸软骨素A吸收峰。     

紫外分光光度法测定润洁滴眼液中维生素B12的含量

紫外分光光度法测定润洁中维生素B_(12)的含量,可简化检验步骤,方便快捷。     

HPLC测定复方妥布霉素滴眼液中苯扎氯铵含量

目的建立HPLC测定复方妥布霉素滴眼液中苯扎氯铵含量的方法。方法以辛烷基硅烷键合硅胶为填充剂;以0.1mol/L乙酸钠溶液(冰乙酸调pH至5.0)-乙腈(40:60)为流动相;检测波长262 nm;流速1.0 mL/min;柱温35℃;进样量20μL。结果苯扎氯铵在0.0645~1.613μg范围内呈良好的线性关系(r=1.000);苯扎氯铵的检测限为8.5 ng,定量限为21.3 ng;苯扎氯铵平均回收率为100.8%(n=9),RSD=1.1%;空白溶液对苯扎氯铵测定无干扰。结论此法准确、可靠,可有效地控制复方妥布霉素滴眼液中苯扎氯铵的含量。     

Unusual presentation of a case of Sjogren's syndrome with neurological and ocular manifestation

Sjogren's syndrome is an autoimmune disease that commonly presents to the ophthalmologist as a dry eye disease. We report an unusual presentation of a case of Sjogren's syndrome. A 33-year-old man presented with lid swelling, pseudomembraneous conjunctivitis with central corneal epithelial defect and history of limb weakness for past 2 years. There was progressive enlargement of the epithelial defect and conjunctival-scleral necrosis developed during follow-up. Evaluation for underlying connective tissue disorder was positive for SS-B/La antibody and, the rheumatoid factor, anti nuclear antibody, anti neutrophil cytoplasmic antibody titres were negative. Patient was diagnosed as a case of Primary Sjogren's syndrome. Resolution of the conjunctival-scleral necrosis occurred following treatment with combination of cyclosporine and prednisolone. Paramedian tarsorrhaphy was performed to promote healing of the corneal epithelium. The corneal epithelium healed, conjunctival-scleral necrosis resolved completely and the visual acuity improved to 6/36 in the right eye after 3 months of immunosuppressive therapy. The immunosuppressive therapy was discontinued after completion of 6 months of treatment. After 6 months follow-up of stopping immunosuppressive therapy, the ocular and systemic condition is stable.     

Application of systane complete for the treatment of contact lens discomfort

PurposeTo understand the safety of treating contact lens (CL) discomfort with a new artificial tear when it is directly applied to a CL-wearing eye.MethodsThis was a two-week, two-visit, double-masked study that randomized participants with CL discomfort to use Systane Complete (artificial tear), Sensitive Eyes (rewetting drop), or no treatment. Drops were applied before, twice during, and after CL use each day. Corneal staining served as the primary safety metric. Conjunctival staining, tear break-up time, Schirmer’s test, CL comfort (Contact Lens Dry Eye Questionnaire-8 [CLDEQ-8]), and dry eye symptoms (Standardized Patient Evaluation of Eye Dryness [SPEED]) were also evaluated.ResultsThis study recruited 73 participants with a mean age of 30.3 ± 11.5 years; 18 % of the participants were male. There were no significant changes in ocular surface signs from baseline or between the artificial tear and rewetting drop groups after two weeks (p ≥ 0.05). Participants in the artificial tear and rewetting drop groups had significant improvements in CLDEQ-8 scores after two weeks of treatment compared with baseline (p < 0.0001), though scores for this test were not significantly different between these groups after two weeks (p = 0.94). CLDEQ-8 scores were significantly better in the artificial tear and rewetting drop groups compared with no treatment after two weeks (p < 0.0001).ConclusionsBoth drops were found to be safe for use with CLs while also significantly improving ocular symptoms compared to no treatment after two weeks of use.     

Evaluation estrogen,progesteron and androgen receptor expressions in corneal epithelium in keratoconus

PurposeTo evaluate the role of sex steroid hormone receptors in corneal epithelium in etiopathogenesis of keratoconus (KC).MethodsThirty patients with KC who were planned for corneal collagen-crosslinking and 20 patients who were planned for excimer laser for refractive errors included in this study. Corneal epitheliums were curated mechanically during surgeries. Right eyes were evaluated immunohistochemically and left eyes were evaluated by quantitative polymerase chain reaction (qPCR) to investigate estrogenα, estrogenβ, progesterone and androgen receptors.ResultsImmunohistochemically, staining for progesterone and androgen receptors did not significantly differ between KC and control groups (p > 0.05). None of the cases had staining for estrogenα and estrogenβ receptors. qPCR showed that mRNA expressions of estrogenα and androgen receptors were significantly higher in the KC group (p < 0.001).ConclusionA significantly higher rate of estrogenα and androgen receptor expressions in corneal epithelium from patients with KC through qPCR supports a possible relation between KC and sex steroid hormones.